NCT05077527View on ClinicalTrials.gov

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
AIDS-Related Diffuse Large B-cell LymphomaAIDS-Related Non-Hodgkin LymphomaHIV InfectionRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Grade 3b Follicular LymphomaRefractory High Grade B-Cell LymphomaRefractory Non-Hodgkin LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Axicabtagene Ciloleucel

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

60612

RECRUITING

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

AIDS Malignancy Consortium

NETWORK